Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin in Nonobstructive Hypertrophic Cardiomyopathy
NCT06433050Phase 1Recruiting
- Sponsor
- University of Pennsylvania
- Start
- Dec 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sotagliflozin in hypertrophic cardiomyopathy (HCM) (2 arms), sponsored by University of Pennsylvania. Primary endpoints: Number of participants with treatment-related adverse events at 28 weeks, Intracavitary obstruction at 28 weeks and 3 more. Started Dec 2024; status: recruiting.
02
Drugs
sotagliflozin
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT06433050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06433050.